<DOC>
	<DOCNO>NCT01173016</DOCNO>
	<brief_summary>This single center pilot study Laronidase give weekly two year patient Hurler syndrome , also know mucopolysaccharide IH ( MPS I , Hurler syndrome ) , previously treat allogeneic transplant .</brief_summary>
	<brief_title>Administration IV Laronidase Post Bone Marrow Transplant Hurler</brief_title>
	<detailed_description>The primary objective pilot study determine feasibility give weekly Laronidase 2 year patient Hurler syndrome allogeneic transplantation . Specifically , ) ability enroll patient , ii ) continue compliance throughout study drug administration testing , well iii ) relevance various endpoint determination assess . The finding pilot study use ass whether subsequent large study conduct . Secondary Objectives : The secondary objective study focus toxicity associate weekly Laronidase patient population , evaluation variety test efficacy parameter would utilized measure outcomes determine benefit patient treat subsequent large study . Eligible patient receive Laronidase infusion several hour week local site . The dose enzyme standard dos recommend Genzyme .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Mucopolysaccharidosis I</mesh_term>
	<criteria>Mucopolysaccharidosis type IH ( MPS I , Hurler syndrome ) treat prior allogeneic transplant &gt; 2 year previously Age &lt; 14 year old &gt; 10 % engraft base recent testing ( &lt; 4 month prior enrollment ) Willing commit travel University Minnesota every 6 month Written inform consent prior performance study relate procedure Previous administration Laronidase enzyme &gt; 3 month post transplantation Anticipated survival le 2 year History cardiac pulmonary insufficiency , include ejection fraction ( EF ) &lt; 40 % require continuous supplemental oxygen</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>14 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>mucopolysaccharide IH ( MPS IH )</keyword>
</DOC>